These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17643814)

  • 1. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt Signalling Drives Context-Dependent Differentiation or Proliferation in Neuroblastoma.
    Szemes M; Greenhough A; Melegh Z; Malik S; Yuksel A; Catchpoole D; Gallacher K; Kollareddy M; Park JH; Malik K
    Neoplasia; 2018 Apr; 20(4):335-350. PubMed ID: 29505958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
    Evans L; Chen L; Milazzo G; Gherardi S; Perini G; Willmore E; Newell DR; Tweddle DA
    Cancer Lett; 2015 Jul; 363(1):37-45. PubMed ID: 25843293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop.
    Gualdrini F; Corvetta D; Cantilena S; Chayka O; Tanno B; Raschellà G; Sala A
    Oncotarget; 2010 Aug; 1(4):278-288. PubMed ID: 21304178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex.
    Papadopoulos D; Ha SA; Fleischhauer D; Uhl L; Russell TJ; Mikicic I; Schneider K; Brem A; Valanju OR; Cossa G; Gallant P; Schuelein-Voelk C; Maric HM; Beli P; Büchel G; Vos SM; Eilers M
    Mol Cell; 2024 Jun; 84(11):2070-2086.e20. PubMed ID: 38703770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
    Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on the role of MYCN in retinoblastoma by inhibiting p53 and activating wnt/βcatenin/Fra-1 signaling pathway by reducing DKK3.
    Chen X; Ouyang L; Ke N; Pi L; Zhou X
    Drug Dev Res; 2024 Aug; 85(5):e22222. PubMed ID: 39003564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is MYCN Overexpression Associated With Poor Outcome in
    Andrews A; Terry J
    Pediatr Dev Pathol; 2024; 27(3):282-283. PubMed ID: 38360554
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.
    Hansford LM; Thomas WD; Keating JM; Burkhart CA; Peaston AE; Norris MD; Haber M; Armati PJ; Weiss WA; Marshall GM
    Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12664-9. PubMed ID: 15314226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Author(s)' Reply: Is MYCN Overexpression Associated With Poor Outcome in
    Zhao M; Shu Y; Gu W; Tang H; Mao J
    Pediatr Dev Pathol; 2024; 27(3):284-285. PubMed ID: 38360532
    [No Abstract]   [Full Text] [Related]  

  • 11. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.
    Salib A; Jayatilleke N; Seneviratne JA; Mayoh C; De Preter K; Speleman F; Cheung BB; Carter DR; Marshall GM
    Oncogene; 2024 Jan; 43(5):363-377. PubMed ID: 38049564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Wnt antagonist Dickkopf-1 and its receptors are coordinately regulated during early human adipogenesis.
    Christodoulides C; Laudes M; Cawthorn WP; Schinner S; Soos M; O'Rahilly S; Sethi JK; Vidal-Puig A
    J Cell Sci; 2006 Jun; 119(Pt 12):2613-2620. PubMed ID: 16763196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
    Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
    Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-linked glycan profiling in neuroblastoma cell lines.
    Hu Y; Mayampurath A; Khan S; Cohen JK; Mechref Y; Volchenboum SL
    J Proteome Res; 2015 May; 14(5):2074-81. PubMed ID: 25730103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
    Barone G; Anderson J; Pearson AD; Petrie K; Chesler L
    Clin Cancer Res; 2013 Nov; 19(21):5814-21. PubMed ID: 23965898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.
    Wei SJ; Nguyen TH; Yang IH; Mook DG; Makena MR; Verlekar D; Hindle A; Martinez GM; Yang S; Shimada H; Reynolds CP; Kang MH
    Cell Death Dis; 2020 May; 11(5):368. PubMed ID: 32409685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.
    Hartman ML; Talar B; Noman MZ; Gajos-Michniewicz A; Chouaib S; Czyz M
    PLoS One; 2014; 9(4):e95157. PubMed ID: 24733089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelators as Antineuroblastomas Agents.
    D'Acunto CW; Gbelcová H; Kaplánek R; Pospíšilová M; Havlík M; Ruml T
    Physiol Res; 2023 Oct; 72(S3):S277-S286. PubMed ID: 37888971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
    Sun Y; Liu PY; Scarlett CJ; Malyukova A; Liu B; Marshall GM; MacKenzie KL; Biankin AV; Liu T
    Oncogene; 2014 Jun; 33(23):2987-94. PubMed ID: 23812427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers.
    Stokes ME; Vasciaveo A; Small JC; Zask A; Reznik E; Smith N; Wang Q; Daniels J; Forouhar F; Rajbhandari P; Califano A; Stockwell BR
    Cell Chem Biol; 2024 Apr; 31(4):805-819.e9. PubMed ID: 38061356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.